Osteoporoz u zhenshchin v postmenopauze
- Authors: Yakushevskaya O.V1
-
Affiliations:
- Issue: No 10 (2014)
- Pages: 44-47
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287004
- ID: 287004
Cite item
Open Access
Access granted
Abstract
Postmenopausal osteoporosis (OP) - a systemic skeletal disease characterized by low bone mass and microarchitectural defection of bone tissue, which leads to increased bone fragility, a one of the social problems in the developed countries [1]. OP incidence is increased with age, and complications associated are increased with increasing life expectancy. These problems are particularly relevant for women and determined by high prevalence among the population, multifactorial nature, high frequency of disability, and deaths in some cases [2]. Therefore, prevention of OP and reduction of fracture risk remains challenge for clinicians.
Full Text
References
- Лесняк О.М. Аудит состояния проблемы остеопороза в странах восточной Европы и центральной Азии 2010. Остеопороз и остеопения. 2011; 2: 3-6.
- Лесняк О.М., Беневоленская Л.И. Клинические рекомендации «Остеопороз. Диагностика, профилактика и лечение». М., 2009.
- Михайлов Е.Е., Беневоленская Л.И. Эпидемиология остеопороза и переломов. В кн. «Руководство по остеопорозу». М., 2003. С. 10-53.
- Сметник В.П., Кулаков В.И. Руководство по климактерию. М., 2001.
- Overbeek G.A., van Vliet N.P., van der Vies J., et al. The influence of steroids on the skeleton. Arch Int Pharmacodyn Ther. 1969; 182: 420.
- Sandker G.W., Vos R.M., Delbressine L.P. Metabolism of three pharmacologically active drugs in isolated human and fat hepatocytes: analysis of interspecies variability and comparison with metabolism in vivo. Xenobiotica. 1994; 24: 143-55.
- Tax L., Goorissen E.M., Kicovic P.M. Clinical profile of Org OD14. Maturitas. 1987(Suppl 1): 3-13.
- Vos R.M., Krebbers S.F., Verhoeven C.H., Delbressine L.P. The in vivo human metabolism of tibolone. Drug Metab. Dispos. 2002; 3: 106-12.
- Markiewicz L., Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J. Steroid Biochem. 1990; 35: 535-41.
- Lindsay R., Hart D.M., Kraszewski A. Prospective doubleblind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br. Med. J. 1980; 280: 1207-09.
- de Gooyer M.E., Deckers G.H., Schoonen W.G., et al. Receptor profi ling and endocrine interactions of tibolone. Steroids. 2003; 68: 21-30.
- Ederveen A.G., Kloosterboer H.J. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J. Bone Miner Res. 2001; 16: 1651-57.
- Gallagher J.C., Baylink D.J., Freeman R., McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J. Clin. Endocrinol. Metab. 2001; 86: 4717-26.
- Rymer J., Robinson J., Fogelman I. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos Int. 2001; 12: 478-83.
- Cummings S.R., Ettinger B, Delmas P.D. The effects of tibolone in older postmenopausal women. N. Engl. J. Med. 2008; 359: 697-708.
Supplementary files
